IHH Healthcare faces near-term growth challenges in key markets despite long-term potential for ROA and valuation improvement. Learn why IHHHF stock is a hold.

Bharat Biotech to launch Hillchol, its oral cholera vaccine, amid a global shortage. With Phase III trials completed and 200M ...